Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PC-300 is a herbal medicinal formulation administered as a tea, composed of a combination of *Eryngium heterophyllum* (commonly known as Hierba del sapo) and *Amphipterygium adstringens* (commonly known as Cuachalalate). It is primarily investigated in Mexico for its hypolipidemic properties, specifically for the treatment of hypertriglyceridemia and hypercholesterolemia. The formulation leverages the traditional medicinal properties of *Eryngium heterophyllum*, which is noted for its ability to lower serum lipid levels, and *Amphipterygium adstringens*, which is traditionally used for its anti-inflammatory and gastroprotective effects. In clinical settings, PC-300 has been evaluated in comparative studies against conventional fibrate therapies such as bezafibrate, demonstrating significant efficacy in reducing total cholesterol and triglyceride levels when combined with a low-lipid diet.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PC-300.